Skip to main content

16.05.2024 | Review

Diagnosis and management of primary hyperoxalurias: best practices

verfasst von: Mini Michael, Elizabeth Harvey, Dawn S. Milliner, Yaacov Frishberg, David J. Sas, Juan Calle, Lawrence Copelovitch, Kristina L. Penniston, Jeffrey Saland, Michael J. G. Somers, Michelle A. Baum

Erschienen in: Pediatric Nephrology

Einloggen, um Zugang zu erhalten

Abstract

The primary hyperoxalurias (PH 1, 2, and 3) are rare autosomal recessive disorders of glyoxylate metabolism resulting in hepatic overproduction of oxalate. Clinical presentations that should prompt consideration of PH include kidney stones, nephrocalcinosis, and kidney failure of unknown etiology, especially with echogenic kidneys on ultrasound. PH1 is the most common and severe of the primary hyperoxalurias with a high incidence of kidney failure as early as infancy. Until the recent availability of a novel RNA interference (RNAi) agent, PH care was largely supportive of eventual need for kidney/liver transplantation in PH1 and PH2. Together with the Oxalosis and Hyperoxaluria Foundation, the authors developed a diagnostic algorithm for PH1 and in this report outline best clinical practices related to its early diagnosis, supportive treatment, and long-term management, including the use of the novel RNAi. PH1-focused approaches to dialysis and kidney/liver transplantation for PH patients with progression to chronic kidney disease/kidney failure and systemic oxalosis are suggested. Therapeutic advances for this devastating disease heighten the importance of early diagnosis and informed treatment.

Graphical abstract

Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717–727PubMedCrossRef Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717–727PubMedCrossRef
3.
Zurück zum Zitat Danpure CJ, Jennings R (1986) Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 201:20–24PubMedCrossRef Danpure CJ, Jennings R (1986) Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett 201:20–24PubMedCrossRef
4.
Zurück zum Zitat Webster KE, Ferree PM, Holmes RP, Cramer SD (2000) Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet 107:176–185PubMedCrossRef Webster KE, Ferree PM, Holmes RP, Cramer SD (2000) Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet 107:176–185PubMedCrossRef
5.
Zurück zum Zitat Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedPubMedCentralCrossRef Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol 6:2289–2295PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635PubMedCrossRef Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621–635PubMedCrossRef
7.
Zurück zum Zitat Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J (2023) Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 19:194-211 Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O, Cerkauskiene R, Ferraro PM, Groen LA, Gupta A, Knebelmann B, Mandrile G, Moochhala SS, Prytula A, Putnik J, Rumsby G, Soliman NA, Somani B, Bacchetta J (2023) Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 19:194-211
9.
Zurück zum Zitat Sas DJ, Harris C, Milliner DS (2019) Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis 47:79–89PubMedCrossRef Sas DJ, Harris C, Milliner DS (2019) Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis 47:79–89PubMedCrossRef
10.
Zurück zum Zitat Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 28:1923–1942PubMedPubMedCentralCrossRef Edvardsson VO, Goldfarb DS, Lieske JC, Beara-Lasic L, Anglani F, Milliner DS, Palsson R (2013) Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol 28:1923–1942PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Edvardsson V, Sas D (2022) Urinary stone disease and nephrocalcinosis. In Emma F, et al (ed) Pediatric Nephrology, 8th edn. Springer, Cham Edvardsson V, Sas D (2022) Urinary stone disease and nephrocalcinosis. In Emma F, et al (ed) Pediatric Nephrology, 8th edn. Springer, Cham
12.
Zurück zum Zitat Marangella M, Petrarulo M, Vitale C, Daniele PG, Sammartano S, Cosseddu D, Linari F (1991) Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosis-unrelated renal diseases. Clin Sci (Lond) 81:483–490PubMedCrossRef Marangella M, Petrarulo M, Vitale C, Daniele PG, Sammartano S, Cosseddu D, Linari F (1991) Serum calcium oxalate saturation in patients on maintenance haemodialysis for primary hyperoxaluria or oxalosis-unrelated renal diseases. Clin Sci (Lond) 81:483–490PubMedCrossRef
13.
Zurück zum Zitat Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC (2020) End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15:1056–1065PubMedPubMedCentralCrossRef Milliner DS, McGregor TL, Thompson A, Dehmel B, Knight J, Rosskamp R, Blank M, Yang S, Fargue S, Rumsby G, Groothoff J, Allain M, West M, Hollander K, Lowther WT, Lieske JC (2020) End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15:1056–1065PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E (2021) Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 36:1785–1793PubMedPubMedCentralCrossRef Milliner DS, Cochat P, Hulton SA, Harambat J, Banos A, Dehmel B, Lindner E (2021) Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 36:1785–1793PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB (1999) Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56:268–274PubMedCrossRef Hoppe B, Kemper MJ, Bökenkamp A, Portale AA, Cohn RA, Langman CB (1999) Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56:268–274PubMedCrossRef
16.
Zurück zum Zitat Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2023) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625–634PubMedCrossRef Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2023) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625–634PubMedCrossRef
17.
Zurück zum Zitat Sas DJ, Enders FT, Mehta RA, Tang X, Zhao F, Seide BM, Milliner DS, Lieske JC (2020) Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int 97:786–792PubMedCrossRef Sas DJ, Enders FT, Mehta RA, Tang X, Zhao F, Seide BM, Milliner DS, Lieske JC (2020) Clinical features of genetically confirmed patients with primary hyperoxaluria identified by clinical indication versus familial screening. Kidney Int 97:786–792PubMedCrossRef
18.
Zurück zum Zitat Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324PubMedCrossRef Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation (2014) Medical management of kidney stones: AUA guideline. J Urol 192:316–324PubMedCrossRef
20.
Zurück zum Zitat Cochat P, Groothoff J (2013) Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 28:2273–2281PubMedCrossRef Cochat P, Groothoff J (2013) Primary hyperoxaluria type 1: practical and ethical issues. Pediatr Nephrol 28:2273–2281PubMedCrossRef
21.
Zurück zum Zitat Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7:207–211PubMedCrossRef Leumann E, Hoppe B, Neuhaus T (1993) Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr Nephrol 7:207–211PubMedCrossRef
22.
Zurück zum Zitat Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L (2004) The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 66:2402–2410PubMedCrossRef Meschi T, Maggiore U, Fiaccadori E, Schianchi T, Bosi S, Adorni G, Ridolo E, Guerra A, Allegri F, Novarini A, Borghi L (2004) The effect of fruits and vegetables on urinary stone risk factors. Kidney Int 66:2402–2410PubMedCrossRef
23.
Zurück zum Zitat Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed Massey L (2005) Magnesium therapy for nephrolithiasis. Magnes Res 18:123–126PubMed
24.
Zurück zum Zitat Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS; OxalEurope (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736PubMedCrossRef Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS; OxalEurope (2012) Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27:1729–1736PubMedCrossRef
25.
Zurück zum Zitat Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, Parvin M, Basiri A (2014) Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 63:456–463PubMedCrossRef Noori N, Honarkar E, Goldfarb DS, Kalantar-Zadeh K, Taheri M, Shakhssalim N, Parvin M, Basiri A (2014) Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets. Am J Kidney Dis 63:456–463PubMedCrossRef
26.
Zurück zum Zitat Singh P, Chebib FT, Cogal AG, Gavrilov DK, Harris PC, Lieske JC (2020) Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical). Kidney Int Rep 5:955–958PubMedPubMedCentralCrossRef Singh P, Chebib FT, Cogal AG, Gavrilov DK, Harris PC, Lieske JC (2020) Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical). Kidney Int Rep 5:955–958PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G; OxalEurope Consortium (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204PubMedCrossRef Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, Rumsby G; OxalEurope Consortium (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204PubMedCrossRef
28.
Zurück zum Zitat Fargue S, Rumsby G, Danpure CJ (2013) Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:1776–1783PubMedCrossRef Fargue S, Rumsby G, Danpure CJ (2013) Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:1776–1783PubMedCrossRef
29.
Zurück zum Zitat Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 384(13):1216–1226. https://doi.org/10.1056/NEJMoa2021712. PMID: 33789010CrossRefPubMed Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O’Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van’t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators (2021) Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. N Engl J Med 384(13):1216–1226. https://​doi.​org/​10.​1056/​NEJMoa2021712. PMID: 33789010CrossRefPubMed
30.
Zurück zum Zitat Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol 16:1025–1036PubMedPubMedCentralCrossRef Frishberg Y, Deschênes G, Groothoff JW, Hulton SA, Magen D, Harambat J, Van't Hoff WG, Lorch U, Milliner DS, Lieske JC, Haslett P, Garg PP, Vaishnaw AK, Talamudupula S, Lu J, Habtemariam BA, Erbe DV, McGregor TL, Cochat P; study collaborators (2021) Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial. Clin J Am Soc Nephrol 16:1025–1036PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y; ILLUMINATE-B Workgroup (2022) Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24:654–662PubMedCrossRef Sas DJ, Magen D, Hayes W, Shasha-Lavsky H, Michael M, Schulte I, Sellier-Leclerc AL, Lu J, Seddighzadeh A, Habtemariam B, McGregor TL, Fujita KP, Frishberg Y; ILLUMINATE-B Workgroup (2022) Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. Genet Med 24:654–662PubMedCrossRef
32.
Zurück zum Zitat Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y (2023) Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol 38:1075–1086PubMedCrossRef Hayes W, Sas DJ, Magen D, Shasha-Lavsky H, Michael M, Sellier-Leclerc AL, Hogan J, Ngo T, Sweetser MT, Gansner JM, McGregor TL, Frishberg Y (2023) Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol 38:1075–1086PubMedCrossRef
33.
Zurück zum Zitat Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D (2023) Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am J Kidney Dis 81(2):145-155.e1PubMedCrossRef Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D (2023) Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am J Kidney Dis 81(2):145-155.e1PubMedCrossRef
34.
Zurück zum Zitat Stokes F, Acquaviva-Bourdain C, Hoppe B, Lieske JC, Lindner E, Toulson G, Vaz FM, Rumsby G (2020) Plasma oxalate: comparison of methodologies. Urolithiasis 48:473–480PubMedPubMedCentralCrossRef Stokes F, Acquaviva-Bourdain C, Hoppe B, Lieske JC, Lindner E, Toulson G, Vaz FM, Rumsby G (2020) Plasma oxalate: comparison of methodologies. Urolithiasis 48:473–480PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830 Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825–830
36.
Zurück zum Zitat Derveaux T, Delbeke P, Walraedt S, Raes A, Van Laecke S, Leroy BP, De Zaeytijd J (2016) Detailed clinical phenotyping of oxalate maculopathy in primary hyperoxaluria type 1 and review of the literature. Retina 36:2227–2235PubMedCrossRef Derveaux T, Delbeke P, Walraedt S, Raes A, Van Laecke S, Leroy BP, De Zaeytijd J (2016) Detailed clinical phenotyping of oxalate maculopathy in primary hyperoxaluria type 1 and review of the literature. Retina 36:2227–2235PubMedCrossRef
37.
Zurück zum Zitat Lagies R, Beck BB, Hoppe B, Sreeram N, Udink Ten Cate FE (2013) Apical sparing of longitudinal strain, left ventricular rotational abnormalities, and short-axis dysfunction in primary hyperoxaluria type 1. Circ Heart Fail 6:e45–e47PubMedCrossRef Lagies R, Beck BB, Hoppe B, Sreeram N, Udink Ten Cate FE  (2013) Apical sparing of longitudinal strain, left ventricular rotational abnormalities, and short-axis dysfunction in primary hyperoxaluria type 1. Circ Heart Fail 6:e45–e47PubMedCrossRef
38.
Zurück zum Zitat Sas DJ, Enders FT, Gunderson TM, Mehta RA, Olson JB, Seide BM, Banks CJ, Dehmel B, Pellikka PA, Lieske JC, Milliner DS (2021) Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis. Front Med (Lausanne) 8:592357PubMedCrossRef Sas DJ, Enders FT, Gunderson TM, Mehta RA, Olson JB, Seide BM, Banks CJ, Dehmel B, Pellikka PA, Lieske JC, Milliner DS (2021) Natural history of clinical, laboratory, and echocardiographic parameters of a primary hyperoxaluria cohort on long term hemodialysis. Front Med (Lausanne) 8:592357PubMedCrossRef
39.
Zurück zum Zitat Fisher D, Hiller N, Drukker A (1995) Oxalosis of bone: report of four cases and a new radiological staging. Pediatr Radiol 25:293–295PubMedCrossRef Fisher D, Hiller N, Drukker A (1995) Oxalosis of bone: report of four cases and a new radiological staging. Pediatr Radiol 25:293–295PubMedCrossRef
40.
Zurück zum Zitat Ben-Shalom E, Cytter-Kuint R, Rinat C, Becker-Cohen R, Tzvi-Behr S, Goichberg J, Peles V, Frishberg Y (2021) Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study. Pediatr Nephrol 36:3123–3132PubMedCrossRef Ben-Shalom E, Cytter-Kuint R, Rinat C, Becker-Cohen R, Tzvi-Behr S, Goichberg J, Peles V, Frishberg Y (2021) Long-term complications of systemic oxalosis in children-a retrospective single-center cohort study. Pediatr Nephrol 36:3123–3132PubMedCrossRef
41.
Zurück zum Zitat Julian BA, Faugere MC, Malluche HH (1987) Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 9:436–440PubMedCrossRef Julian BA, Faugere MC, Malluche HH (1987) Oxalosis in bone causing a radiographical mimicry of renal osteodystrophy. Am J Kidney Dis 9:436–440PubMedCrossRef
42.
Zurück zum Zitat Rootman MS, Mozer-Glassberg Y, Gurevich M, Schwartz M, Konen O (2018) Imaging features of primary hyperoxaluria. Clin Imaging 52:370–376PubMedCrossRef Rootman MS, Mozer-Glassberg Y, Gurevich M, Schwartz M, Konen O (2018) Imaging features of primary hyperoxaluria. Clin Imaging 52:370–376PubMedCrossRef
43.
Zurück zum Zitat El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, Kharrat K (2008) Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop 2:205–210PubMedPubMedCentralCrossRef El Hage S, Ghanem I, Baradhi A, Mourani C, Mallat S, Dagher F, Kharrat K (2008) Skeletal features of primary hyperoxaluria type 1, revisited. J Child Orthop 2:205–210PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Correction to: three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2497–2498PubMedCrossRef Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Correction to: three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2497–2498PubMedCrossRef
45.
Zurück zum Zitat Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2083–2092PubMedCrossRef Merz LM, Born M, Kukuk G, Sprinkart AM, Becker I, Martin-Higueras C, Hoppe B (2023) Three Tesla magnetic resonance imaging detects oxalate osteopathy in patients with primary hyperoxaluria type I. Pediatr Nephrol 38:2083–2092PubMedCrossRef
46.
Zurück zum Zitat Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, Guebre-Egziabher F, Dohin B, Kohler R, Cochat P (2010) Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers. Pediatr Nephrol 25:1081–1089PubMedCrossRef Bacchetta J, Fargue S, Boutroy S, Basmaison O, Vilayphiou N, Plotton I, Guebre-Egziabher F, Dohin B, Kohler R, Cochat P (2010) Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers. Pediatr Nephrol 25:1081–1089PubMedCrossRef
47.
Zurück zum Zitat Tonnelet D, Benali K, Rasmussen C, Goulenok T, Piekarski E (2020) Diffuse hypermetabolic bone marrow infiltration in severe primary hyperoxaluria on FDG PET. Clin Nucl Med 45(6):e296–e298PubMedCrossRef Tonnelet D, Benali K, Rasmussen C, Goulenok T, Piekarski E (2020) Diffuse hypermetabolic bone marrow infiltration in severe primary hyperoxaluria on FDG PET. Clin Nucl Med 45(6):e296–e298PubMedCrossRef
48.
Zurück zum Zitat Bacchetta J, Boivin G, Cochat P (2016) Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 31:1–6PubMedCrossRef Bacchetta J, Boivin G, Cochat P (2016) Bone impairment in primary hyperoxaluria: a review. Pediatr Nephrol 31:1–6PubMedCrossRef
49.
Zurück zum Zitat Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709PubMedCrossRef Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709PubMedCrossRef
50.
Zurück zum Zitat Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS (2014) Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 14:1433–1438PubMedPubMedCentralCrossRef Lorenz EC, Lieske JC, Seide BM, Meek AM, Olson JB, Bergstralh EJ, Milliner DS (2014) Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. Am J Transplant 14:1433–1438PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570PubMedPubMedCentralCrossRef Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC; Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2022) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625-634 Mandrile G, Beck B, Acquaviva C, Rumsby G, Deesker L, Garrelfs S, Gupta A, Bacchetta J, Groothoff J; OxalEurope Consortium/Erknet Guideline Workgroup On Hyperoxaluria (2022) Genetic assessment in primary hyperoxaluria: why it matters. Pediatr Nephrol 38:625-634
53.
Zurück zum Zitat Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331:1553–1558PubMedCrossRef Milliner DS, Eickholt JT, Bergstralh EJ, Wilson DM, Smith LH (1994) Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med 331:1553–1558PubMedCrossRef
54.
Zurück zum Zitat Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ (2015) Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve 51:449–454PubMedPubMedCentralCrossRef Berini SE, Tracy JA, Engelstad JK, Lorenz EC, Milliner DS, Dyck PJ (2015) Progressive polyradiculoneuropathy due to intraneural oxalate deposition in type 1 primary hyperoxaluria. Muscle Nerve 51:449–454PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Biebuyck N, Destombes C, Prakash R, Boyer O (2023) Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi? J Nephrol 36:1473–1476PubMedCrossRef Biebuyck N, Destombes C, Prakash R, Boyer O (2023) Is withdrawal of nocturnal hyperhydration possible in children with primary hyperoxaluria treated with RNAi? J Nephrol 36:1473–1476PubMedCrossRef
56.
Zurück zum Zitat Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103:207–217 Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, Tönshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B; PHYOX2 study investigators (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103:207–217
57.
Zurück zum Zitat Martin-Higueras C, Feldkötter M, Hoppe B (2021) Is stiripentol truly effective for treating primary hyperoxaluria? Clin Kidney J 14:442–444PubMedCrossRef Martin-Higueras C, Feldkötter M, Hoppe B (2021) Is stiripentol truly effective for treating primary hyperoxaluria? Clin Kidney J 14:442–444PubMedCrossRef
58.
Zurück zum Zitat Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR (2022) CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria. Mol Ther Methods Clin Dev 25:137–146PubMedPubMedCentralCrossRef Martinez-Turrillas R, Martin-Mallo A, Rodriguez-Diaz S, Zapata-Linares N, Rodriguez-Marquez P, San Martin-Uriz P, Vilas-Zornoza A, Calleja-Cervantes ME, Salido E, Prosper F, Rodriguez-Madoz JR (2022) CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria. Mol Ther Methods Clin Dev 25:137–146PubMedPubMedCentralCrossRef
59.
Zurück zum Zitat Sellier-Leclerc AL, Metry E, Clave S, Perrin P, Acquaviva-Bourdain C, Levi C, Crop M, Caillard S, Moulin B, Groothoff J, Bacchetta J (2023) Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases. Nephrol Dial Transplant 38:517–521PubMedCrossRef Sellier-Leclerc AL, Metry E, Clave S, Perrin P, Acquaviva-Bourdain C, Levi C, Crop M, Caillard S, Moulin B, Groothoff J, Bacchetta J (2023) Isolated kidney transplantation under lumasiran therapy in primary hyperoxaluria type 1: a report of five cases. Nephrol Dial Transplant 38:517–521PubMedCrossRef
60.
Zurück zum Zitat Breeggemann MC, Gluck SL, Stoller ML, Lee MM (2023) A case report of kidney-only transplantation in primary hyperoxaluria type 1: a novel approach with the use of nedosiran. Case Rep Nephrol Dial 13:63–69PubMedPubMedCentralCrossRef Breeggemann MC, Gluck SL, Stoller ML, Lee MM (2023) A case report of kidney-only transplantation in primary hyperoxaluria type 1: a novel approach with the use of nedosiran. Case Rep Nephrol Dial 13:63–69PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126PubMedCrossRef Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS; Investigators of Rare Kidney Stone Consortium (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126PubMedCrossRef
62.
Zurück zum Zitat Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:3608 Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:3608
63.
Zurück zum Zitat Watts RW, Veall N, Purkiss P (1984) Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 66:591–597PubMedCrossRef Watts RW, Veall N, Purkiss P (1984) Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci (Lond) 66:591–597PubMedCrossRef
64.
Zurück zum Zitat Marangella M, Cosseddu D, Petrarulo M, Vitale C, Linari F (1993) Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant 8:1333–1337PubMed Marangella M, Cosseddu D, Petrarulo M, Vitale C, Linari F (1993) Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant 8:1333–1337PubMed
65.
Zurück zum Zitat Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F (1992) Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 19:546–553PubMedCrossRef Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F (1992) Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 19:546–553PubMedCrossRef
66.
Zurück zum Zitat Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648PubMedCrossRef Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642–1648PubMedCrossRef
67.
Zurück zum Zitat Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F (2017) Impact of regular or extended hemodialysis and hemodialfiltration on plasma oxalate concentrations in patients with end-stage renal disease. Kidney Int Rep 2:1050–1058PubMedPubMedCentralCrossRef Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F (2017) Impact of regular or extended hemodialysis and hemodialfiltration on plasma oxalate concentrations in patients with end-stage renal disease. Kidney Int Rep 2:1050–1058PubMedPubMedCentralCrossRef
68.
Zurück zum Zitat Franssen CF (2005) Oxalate clearance by haemodialysis–a comparison of seven dialysers. Nephrol Dial Transplant 20:1916–1921PubMedCrossRef Franssen CF (2005) Oxalate clearance by haemodialysis–a comparison of seven dialysers. Nephrol Dial Transplant 20:1916–1921PubMedCrossRef
69.
Zurück zum Zitat Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC (2015) Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87:623–631PubMedCrossRef Tang X, Bergstralh EJ, Mehta RA, Vrtiska TJ, Milliner DS, Lieske JC (2015) Nephrocalcinosis is a risk factor for kidney failure in primary hyperoxaluria. Kidney Int 87:623–631PubMedCrossRef
70.
Zurück zum Zitat Díaz C, Catalinas FG, de Alvaro F, Torre A, Sánchez C, Costero O (2004) Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantation: case report. Ther Apher Dial 8:52–55PubMedCrossRef Díaz C, Catalinas FG, de Alvaro F, Torre A, Sánchez C, Costero O (2004) Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantation: case report. Ther Apher Dial 8:52–55PubMedCrossRef
71.
Zurück zum Zitat Plumb TJ, Swee ML, Fillaus JA (2013) Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. Am J Kidney Dis 62:1155–1159PubMedCrossRef Plumb TJ, Swee ML, Fillaus JA (2013) Nocturnal home hemodialysis for a patient with type 1 hyperoxaluria. Am J Kidney Dis 62:1155–1159PubMedCrossRef
72.
Zurück zum Zitat Yamauchi T, Quillard M, Takahashi S, Nguyen-Khoa M (2001) Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant 16:2407–2411PubMedCrossRef Yamauchi T, Quillard M, Takahashi S, Nguyen-Khoa M (2001) Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant 16:2407–2411PubMedCrossRef
73.
Zurück zum Zitat Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC (2014) Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol 39:376–382PubMedCrossRef Tang X, Voskoboev NV, Wannarka SL, Olson JB, Milliner DS, Lieske JC (2014) Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria. Am J Nephrol 39:376–382PubMedCrossRef
74.
Zurück zum Zitat Cochat P, Fargue S, Harambat J (2010) Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 15:590–593PubMedCrossRef Cochat P, Fargue S, Harambat J (2010) Primary hyperoxaluria type 1: strategy for organ transplantation. Curr Opin Organ Transplant 15:590–593PubMedCrossRef
75.
Zurück zum Zitat Cornell LD, Amer H, Viehman JK, Mehta RA, Lieske JC, Lorenz EC, Heimbach JK, Stegall MD, Milliner DS; Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators (2022) Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: incidence, risk factors, and effect on renal allograft function. Am J Transplant 22:85–95PubMedCrossRef Cornell LD, Amer H, Viehman JK, Mehta RA, Lieske JC, Lorenz EC, Heimbach JK, Stegall MD, Milliner DS; Rare Kidney Stone Consortium Primary Hyperoxaluria (RKSC PH) investigators (2022) Posttransplant recurrence of calcium oxalate crystals in patients with primary hyperoxaluria: incidence, risk factors, and effect on renal allograft function. Am J Transplant 22:85–95PubMedCrossRef
76.
Zurück zum Zitat Villani V, Gupta N, Elias N, Vagefi PA, Markmann JF, Paul E, Traum AZ, Yeh H (2017) Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: a case report. Pediatr Transplant 21(3). Villani V, Gupta N, Elias N, Vagefi PA, Markmann JF, Paul E, Traum AZ, Yeh H (2017) Bilateral native nephrectomy reduces systemic oxalate level after combined liver-kidney transplant: a case report. Pediatr Transplant 21(3).
77.
Zurück zum Zitat Mor E, Nesher E, Ben-Ari Z, Weissman I, Shaharabani E, Eizner S, Solomonov E, Rahamimov R, Braun M (2013) Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 19:646–648PubMedCrossRef Mor E, Nesher E, Ben-Ari Z, Weissman I, Shaharabani E, Eizner S, Solomonov E, Rahamimov R, Braun M (2013) Sequential liver and kidney transplantation from a single living donor in two young adults with primary hyperoxaluria type 1. Liver Transpl 19:646–648PubMedCrossRef
78.
Zurück zum Zitat Metry EL, van Dijk LMM, Peters-Sengers H, Oosterveld MJS, Groothoff JW, Ploeg RJ, Stel VS, Garrelfs SF (2021) Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr Nephrol 36:2217–2226PubMedPubMedCentralCrossRef Metry EL, van Dijk LMM, Peters-Sengers H, Oosterveld MJS, Groothoff JW, Ploeg RJ, Stel VS, Garrelfs SF (2021) Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr Nephrol 36:2217–2226PubMedPubMedCentralCrossRef
79.
Zurück zum Zitat Xiang J, Chen Z, Xu F, Mei S, Li Z, Zhou J, Dong Y, Gu Y, Huang Z, Hu Z (2020) Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database. BMC Gastroenterol 20:208PubMedPubMedCentralCrossRef Xiang J, Chen Z, Xu F, Mei S, Li Z, Zhou J, Dong Y, Gu Y, Huang Z, Hu Z (2020) Outcomes of liver-kidney transplantation in patients with primary hyperoxaluria: an analysis of the scientific registry of transplant recipients database. BMC Gastroenterol 20:208PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Dhondup T, Lorenz EC, Milliner DS, Lieske JC. (2018) Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am J Transplant 18:253–257PubMedCrossRef Dhondup T, Lorenz EC, Milliner DS, Lieske JC. (2018) Combined liver-kidney transplantation for primary hyperoxaluria type 2: a case report. Am J Transplant 18:253–257PubMedCrossRef
81.
Zurück zum Zitat Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501PubMedPubMedCentralCrossRef Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493–2501PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145PubMedPubMedCentralCrossRef Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136–2145PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Lee E, Ramos-Gonzalez G, Rodig N, Elisofon S, Vakili K, Kim HB (2018) Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver–kidney transplantation for primary hyperoxaluria type 1. Pediatr Nephrol 33:881–887 Lee E, Ramos-Gonzalez G, Rodig N, Elisofon S, Vakili K, Kim HB (2018) Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver–kidney transplantation for primary hyperoxaluria type 1. Pediatr Nephrol 33:881–887
Metadaten
Titel
Diagnosis and management of primary hyperoxalurias: best practices
verfasst von
Mini Michael
Elizabeth Harvey
Dawn S. Milliner
Yaacov Frishberg
David J. Sas
Juan Calle
Lawrence Copelovitch
Kristina L. Penniston
Jeffrey Saland
Michael J. G. Somers
Michelle A. Baum
Publikationsdatum
16.05.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
Pediatric Nephrology
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-024-06328-2

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.